An independent, evidence-based review of AG1 (Athletic Greens) ingredient efficacy, regulatory standing, consumer complaints, and what the available outcomes data actually show.
An independent clinical review of Winona's menopause telehealth platform, HRT prescribing model, pricing, and how it compares to alternatives, with primary-source citations throughout.
A deep dive into bremelanotide (Vyleesi) cardiovascular effects, blood pressure changes, long-term safety data from RECONNECT, and clinical guidance for patients with cardiac risk factors.
Everything clinicians and patients need to know about bremelanotide (Vyleesi) storage temperatures, shelf life, auto-injector stability, and what to do if a dose is compromised.
A detailed guide to Humana's coverage of Eliquis (apixaban) across Medicare Advantage, Medicare Part D, and commercial plans. Learn about formulary tiers, prior authorization, copay programs, and step therapy requirements.
A clinician-level review of tadalafil's pipeline: new delivery systems, combination therapies, emerging indications, and the trials reshaping how this PDE5 inhibitor will be used beyond erectile dysfunction and BPH.
When and how to safely restart tadalafil after acute illness, including cardiovascular screening, drug interactions, dose adjustments, and evidence-based clinical protocols.
A prescriber-level review of aromatase inhibitor drug class pharmacology, adverse-event profiles, and evidence-based management protocols for musculoskeletal, bone, cardiovascular, and CNS toxicities in breast cancer and off-label male hypogonadism settings.
Answer: estrogens counteract Arimidex by opposing its mechanism. See the full aromatase inhibitor drug interaction table with severity and management steps.
A prescriber-level review of aromatase inhibitor pharmacology, dosing, and clinical management across special populations including postmenopausal women, men with hypogonadism, adolescents, and patients with hepatic or renal impairment.
A prescriber-level guide to bisphosphonate pharmacology, indication coding, prior authorization strategy, and step-therapy navigation for alendronate, risedronate, zoledronic acid, and ibandronate.
A prescriber-level monograph covering the copper peptides drug class: mechanisms, pharmacology, clinical evidence, dosing, safety, and comparisons with prototype GHK-Cu. Includes citations to primary literature.
A physician-level guide to copper peptide pharmacology, GHK-Cu dosing protocols, titration schedules, tapering strategies, and safety monitoring for skin and hair regeneration.
A prescriber-oriented overview of how growth hormone secretagogues (ipamorelin, CJC-1295, sermorelin, MK-677) are typically titrated and tapered in compounding practice, with monitoring checkpoints and the boundary between general protocol patterns and individualized prescribing.
A prescriber-level monograph covering the pharmacology, clinical trial data, dosing, safety, and guideline recommendations for all rapid-acting insulin analogs including lispro, aspart, glulisine, and ultra-rapid formulations.
A prescriber-level guide to meglitinides: drug class pharmacology, dosing, prandial glucose evidence, insurance billing codes, and prior-authorization strategies for repaglinide and nateglinide.
A prescriber-level review of meglitinide pharmacology, dosing, and special-population considerations including renal impairment, hepatic disease, elderly patients, pregnancy, and pediatrics. Includes key trial data, guideline quotes, and a clinical decision framework.
A prescriber-level guide to the melanocortin receptor agonist drug class, covering pharmacology, FDA-approved agents, dosing, required monitoring parameters, adverse-effect management, and drug interactions, with primary-source citations throughout.
A prescriber-level review of PCSK9 inhibitor use across special populations including familial hypercholesterolemia, post-ACS patients, chronic kidney disease, diabetes, elderly patients, and pregnancy, with dosing guidance and key trial data.
A prescriber-level monograph comparing micronized progesterone with synthetic progestins across HRT, luteal support, and cardiovascular risk. Includes dosing, pharmacology, clinical trial data, and guideline recommendations.
A complete drug-drug interaction table comparing micronized progesterone vs synthetic progestins, with dosing, metabolism pathways, and clinical prescribing guidance for HRT and luteal support.
A prescriber-level guide to oral micronized progesterone and synthetic progestins: pharmacology, dosing titration, tapering protocols, and clinical decision frameworks for menopausal HRT and luteal support.
A complete MD/PharmD-level guide to the siRNA lipid therapeutics drug class, inclisiran prescribing, billing codes, and prior authorization strategies for twice-yearly LDL reduction.
A prescriber-level guide to siRNA lipid-lowering agents, covering inclisiran pharmacology, patient selection, dosing, and how to choose between available agents based on current trial data and guidelines.
A prescriber-level guide to statin titration, tapering, dose adjustments, and switching strategies for HMG-CoA reductase inhibitors, with clinical trial evidence and guideline-based thresholds.
A clinical-level DDI table for all major sulfonylureas, covering pharmacokinetic and pharmacodynamic interactions, severity ratings, and management guidance for prescribers and pharmacists.
A prescriber-level guide to recognizing, grading, and managing adverse events across all testosterone formulation classes, with dosing adjustments, monitoring intervals, and guideline-backed protocols.
A prescriber-level guide to testosterone formulation classes, ICD-10 coding, prior authorization strategy, and formulary navigation for male hypogonadism and related indications.
A comprehensive MD/PharmD-level review of testosterone formulation classes, their pharmacokinetics, and a complete drug-drug interaction table covering anticoagulants, insulin, corticosteroids, and more, with primary-source citations.
A comprehensive MD/PharmD-level guide to the testosterone formulations drug class, covering all delivery routes, laboratory monitoring protocols, dose titration, and safety surveillance for male hypogonadism management.
What the injectable testosterone cypionate and enanthate labels say about dose adjustment, tapering, monitoring and fertility after stopping.
Donepezil treats all Alzheimer's stages by boosting acetylcholine; memantine targets moderate-severe stages via NMDA blockade. Both can be combined.
A guide to insurance coverage for ADHD stimulants like Adderall and Vyvanse, prior authorization steps, 2026 cash prices, and alternatives like modafinil.
Yes, Leqvio (inclisiran) can be added to Lipitor (atorvastatin) rather than replacing it, adding about 50% more LDL-C reduction on top of the statin.
Yes, Vyvanse costs more. Brand Vyvanse runs $380-420/month; generic Adderall XR is $30-60. Generic lisdexamfetamine, since 2023, costs $70-130.
A clinical comparison of semaglutide 2.4 mg (Wegovy) and liraglutide 3 mg (Saxenda) for weight loss, including how to switch safely between them, side-effect profiles, dosing timelines, and head-to-head efficacy data.
A clinical comparison of AndroGel (testosterone gel) and Jatenzo (oral testosterone undecanoate) side-effect profiles, including cardiovascular risk, skin reactions, GI effects, and dosing practicality for men on TRT.
A clinical comparison of testosterone cypionate injections and AndroGel (testosterone gel), including how to switch safely between them, pharmacokinetics, dosing, and which form suits different patient profiles.
A clinical comparison of ipamorelin acetate and ibutamoren (MK-677), covering mechanism, dosing, side effects, and how to switch between them safely.
A detailed head-to-head comparison of finasteride and dutasteride (Avodart) side-effect profiles, efficacy data, and clinical decision-making guidance for androgenetic alopecia and BPH.
A clinical comparison of topical minoxidil 5% for hair loss and isotretinoin for severe acne, including when each is appropriate, how to switch, and what the evidence actually shows.
Mounjaro and retatrutide: what studies show, whether switching or combining is established, and how product, access and population differences matter.
A detailed clinical comparison of oral estradiol and Prometrium (micronized progesterone) side-effect profiles, covering cardiovascular risk, breast tissue effects, mood, sleep, and metabolic impacts, with trial data and dosing guidance.
A comparison of oral micronized progesterone (Prometrium) and oral estradiol, covering mechanism, safety, switching protocols, and which to use when.
Learn how genetics and family history shape menopause timing, symptom severity, and treatment response. Evidence-based guidance from primary trials and society guidelines for women and their clinicians.
Menopause symptoms are frequently mistaken for thyroid disease, depression, anxiety, ADHD, and other conditions. Learn which diagnoses are most often missed, how to tell them apart, and what guidelines say about getting the right diagnosis and treatment.
A guide to recognizing menopause treatment failure, when to switch therapies, and how society guidelines define inadequate response to HRT and non-hormonal options.
Evidence-based caregiver and family resources for metabolic syndrome, including diagnosis criteria, treatment options, lifestyle interventions, and how to support a loved one through dietary, pharmacologic, and monitoring strategies.
Compare metabolic syndrome definitions, ADA and USPSTF screening, AACE and Endocrine Society guidance, and verified diabetes and cardiovascular trial results.
A guide for caregivers and family members supporting someone with NAFLD or MASLD, covering diagnosis, treatment options including resmetirom and GLP-1 receptor agonists, lifestyle interventions, and how to find specialist care.
A comprehensive clinical history of obesity treatment from early dietary regimens to modern GLP-1 receptor agonists, with primary-source citations and guideline references for patients and clinicians.
A comprehensive clinical history of perimenopause treatment from the 1960s through today, covering hormone therapy, the WHI trial fallout, and current evidence-based guidelines for managing symptoms.
A guide to safely discontinuing or tapering cardiovascular medications in patients with established CVD, including what is well established, what is plausible but unproven, and when to get urgent care.
A clinical history of post-surgical recovery care from 19th-century bed rest to modern Enhanced Recovery After Surgery (ERAS) protocols, with an evidence-boundary review of what is well established versus what needs primary-source verification.
A clinical deep-dive into denosumab-associated dermatologic adverse effects, including eczema, cellulitis, alopecia, and rash, with primary-literature citations and practical management guidance.
A clinician-level review of denosumab (Prolia) and its effects on mental health, mood, depression, and neuropsychiatric symptoms. Includes trial data, mechanism analysis, and prescribing guidance.
New clinical research shows weight loss does shift gut microbiome composition, but the relationship is bidirectional and more complex than early studies suggested. Learn what the evidence actually shows, which bacteria matter most, and how this changes clinical practice.
A citation-dense guide to every clinically significant drug-drug interaction with Trulicity (dulaglutide): mechanisms, affected drug classes, management strategies, and the REWIND cardiovascular evidence base.
A guide to dulaglutide (Trulicity) effects on hair and skin, covering clinical trial data, proposed mechanisms, and what patients can expect.
A clinical guide to dulaglutide (Trulicity) seasonal use considerations, covering heat stability, cold-weather injection technique, holiday eating patterns, illness management, and cardiovascular evidence from REWIND.